Co-Authors
This is a "connection" page, showing publications co-authored by DAVID SANGHYUN HONG and MARK J ROUTBORT.
Connection Strength
0.258
-
Targeting ERBB2 (HER2) Amplification Identified by Next-Generation Sequencing in Patients With Advanced or Metastatic Solid Tumors Beyond Conventional Indications. JCO Precis Oncol. 2019; 3.
Score: 0.044
-
Targeting the HGF/MET Axis Counters Primary Resistance to KIT Inhibition in KIT-Mutant Melanoma. JCO Precis Oncol. 2018; 2018.
Score: 0.040
-
MET amplification assessed using optimized FISH reporting criteria predicts early distant metastasis in patients with non-small cell lung cancer. Oncotarget. 2018 Feb 27; 9(16):12959-12970.
Score: 0.039
-
Clinical Use of Precision Oncology Decision Support. JCO Precis Oncol. 2017; 2017.
Score: 0.038
-
Clinical next generation sequencing to identify actionable aberrations in a phase I program. Oncotarget. 2015 Aug 21; 6(24):20099-110.
Score: 0.033
-
Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials. J Clin Oncol. 2015 Sep 01; 33(25):2753-62.
Score: 0.032
-
A decision support framework for genomically informed investigational cancer therapy. J Natl Cancer Inst. 2015 Jul; 107(7).
Score: 0.032